FDA Adverse Event Injury Summary report: N

ARTEGRAFT

MDR report key: 7138873 · Received December 21, 2017

Report

Report Number
2247686-2017-00013
Event Type
Injury
Date Received
December 21, 2017
Date of Event
November 23, 2017
Report Date
December 21, 2017
Manufacturer
ARTEGRAFT, INC
Product Code
LXA
PMA / PMN Number
N16837
Adverse Event
Yes
Product Problem
Yes
Report Source
Manufacturer report
Reporter Location
MO, US
Reporter Occupation
PHYSICIAN

Narratives

Additional Manufacturer Narrative · 1

MULTIPLE REQUESTS WERE MADE TO RETRIEVE ADDITIONAL INFORMATION; HOWEVER, TO DATE, NO ADDITIONAL INFORMATION WAS PROVIDED. PRODUCT CODE, LOT NUMBER, DATE OF IMPLANT, EXACT DATE OF THE EVENT, PATIENT IDENTIFIER AND INFORMATION WERE NOT PROVIDED. A REVIEW OF THE PRODUCTION BATCH RECORDS WAS NOT ABLE TO BE COMPLETED AS THE PRODUCT LOT NUMBER WAS NOT PROVIDED. ANEURYSM IS A KNOWN ISSUE; ARTEGRAFT, INC. IFU ADVERSE REACTION SECTION STATES THAT "TRUE ANEURYSMS HAVE BEEN REPORTED. IN VIEW OF THIS, PATIENTS WITH IMPLANTED ARTEGRAFTS SHOULD BE OBSERVED SO THAT APPROPRIATE ACTION CAN BE TAKEN IF AN ANEURYSM SHOULD OCCUR. THIS ADVERSE REACTION SHOULD ALSO BE CONSIDERED WHEN TREATING CONDITIONS IN WHICH EXTENDED PERIODS OF IMPLANTATION ARE EXPECTED". TO DATE, NO CONFIRMED COMPLAINT TREND WAS IDENTIFIED RELATED TO ANEURYSMAL GRAFTS. ALL PRODUCT QUALITY AND CLINICAL ISSUES WILL CONTINUE TO BE MONITORED WITHIN ARTEGRAFT, INC. QUALITY SYSTEMS, QUALITY ASSURANCE TRENDING. SHOULD ADDITIONAL INFORMATION BECOME AVAILABLE, A FOLLOW-UP REPORT WILL BE SUBMITTED.

Description of Event or Problem · 1

ARTEGRAFT, INC. RECEIVED A PHONE CALL FROM A VASCULAR SURGEON STATING THAT IN 2013 TWO PATIENTS HAD A FEMORAL POPLITEAL BYPASS PROCEDURE WITH ARTEGRAFT (COLLAGEN VASCULAR GRAFT); THE GRAFTS WERE REPORTED AS BECOMING ANEURYSMAL. THIS FILE WILL CAPTURE PATIENT 2 OF 2. THE PATIENT REQUIRED SURGERY ON (B)(6) 2017 TO REPAIR THE ANEURYSM.

Devices

Seq Brand Generic Product Code Manufacturer Model Lot UDI-DI
919608 ARTEGRAFT COLLAGEN VASCULAR GRAFT LXA ARTEGRAFT, INC

Patients

Seq Age Sex Outcome Treatment
1 Required Intervention